ATE317267T1 - Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung - Google Patents

Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung

Info

Publication number
ATE317267T1
ATE317267T1 AT01983349T AT01983349T ATE317267T1 AT E317267 T1 ATE317267 T1 AT E317267T1 AT 01983349 T AT01983349 T AT 01983349T AT 01983349 T AT01983349 T AT 01983349T AT E317267 T1 ATE317267 T1 AT E317267T1
Authority
AT
Austria
Prior art keywords
vaccines
production
immune response
increased immune
vaccine
Prior art date
Application number
AT01983349T
Other languages
English (en)
Inventor
Robert George Brown
Bill Pohajdak
Warwick Charles Kimmins
Original Assignee
Immunovaccine Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovaccine Technologies Inc filed Critical Immunovaccine Technologies Inc
Application granted granted Critical
Publication of ATE317267T1 publication Critical patent/ATE317267T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT01983349T 2000-11-07 2001-10-31 Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung ATE317267T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24607500P 2000-11-07 2000-11-07
US30715901P 2001-07-24 2001-07-24

Publications (1)

Publication Number Publication Date
ATE317267T1 true ATE317267T1 (de) 2006-02-15

Family

ID=26937702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983349T ATE317267T1 (de) 2000-11-07 2001-10-31 Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung

Country Status (9)

Country Link
US (5) US6793923B2 (de)
EP (1) EP1333858B8 (de)
JP (1) JP4164361B2 (de)
AT (1) ATE317267T1 (de)
AU (2) AU2002214861B2 (de)
CA (1) CA2428103C (de)
DE (1) DE60117164T2 (de)
ES (1) ES2258108T3 (de)
WO (1) WO2002038175A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
FR2862306B1 (fr) * 2003-11-17 2008-05-30 Aventis Pasteur Composition vaccinale
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
EP1998800A2 (de) 2006-01-18 2008-12-10 University Of Chicago Zusammensetzungen und verfahren in verbindung mit stayphylokokken-bakterienproteinen
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
CA2700828C (en) * 2007-10-03 2017-01-24 Immunovaccine Technologies Inc. Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
JP2012504660A (ja) 2008-10-06 2012-02-23 ユニバーシティ オブ シカゴ 細菌ｅａｐ、ｅｍｐおよび／またはａｄｓａタンパク質に関連する組成物および方法
US20120027793A1 (en) 2009-01-29 2012-02-02 British Columbia Cancer Agency Branch Compositions comprising chlamydia antigens
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
DK3281947T3 (da) 2009-04-03 2020-05-11 Univ Chicago Sammensætninger og fremgangsmåder relateret til protein A (SPA)-varianter
US9241987B2 (en) 2009-11-20 2016-01-26 The University Of Chicago Methods and compositions related to immunogenic fibrils
US9849174B2 (en) 2009-11-20 2017-12-26 The Board Of Regents Of The University Of Texas System Methods and compositions related to immunogenic fibrils
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
WO2012018628A1 (en) * 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
WO2012034067A1 (en) 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP6317670B2 (ja) 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
ES2855474T3 (es) * 2011-10-06 2021-09-23 Immunovaccine Technologies Inc Composiciones de liposomas que comprenden un adyuvante que activa o incrementa la actividad de TLR2 y usos del mismo
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
CN105324128B (zh) 2013-03-27 2020-09-01 免疫疫苗技术有限公司 用于改善存活蛋白疫苗在癌症治疗中的功效的方法
US20150359880A1 (en) 2014-06-16 2015-12-17 Biomune Company Dual adjuvant vaccine compositions, preparation and uses
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CA2972635A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
US11160861B2 (en) 2015-11-18 2021-11-02 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
EP3452083A4 (de) * 2016-05-04 2020-01-01 ImmunoVaccine Technologies Inc. Impfstoffzusammensetzungen mit einer amphipathische verbindung, einem neoantigen und einem hydrophoben träger sowie verfahren zur verwendung davon
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
CA3242476A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2134869A (en) * 1983-02-15 1984-08-22 Squibb & Sons Inc Method of preparing liposomes and products produced thereby
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5897873A (en) 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US6093406A (en) 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5015476A (en) * 1989-08-11 1991-05-14 Paravax, Inc. Immunization implant and method
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
CA2086094C (en) * 1990-06-29 2000-05-30 Gail L. Barchfeld Vaccine compositions containing liposomes
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
AU4303493A (en) * 1992-06-05 1994-01-04 University Of Dalhousie Use of zona pellucida glycoproteins for immunocontraception
US5736141A (en) * 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
USRE37224E1 (en) * 1992-06-05 2001-06-12 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
ES2270426T3 (es) * 1994-03-18 2007-04-01 Supernus Pharmaceuticals, Inc. Sistema de suministros de farmacos emulsionados.
US5637300A (en) * 1994-08-03 1997-06-10 Dunbar; Bonnie S. Contraceptive vaccine comprising a glycosylated 55 kD zona pellucida protein immunogen and method of use of the same in contraception
US6168804B1 (en) * 1995-06-07 2001-01-02 University Of Alberta Method for eliciting Th1-specific immune response
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU8053898A (en) * 1997-05-28 1998-12-30 Jenner Biotherapies, Inc. Immunogenic compositions
EP1015468A4 (de) * 1997-08-29 2000-09-06 Human Genome Sciences Inc Follistatin-3
US6406719B1 (en) * 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US7087236B1 (en) * 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6790457B1 (en) * 1998-12-22 2004-09-14 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds
WO2000037100A2 (en) * 1998-12-22 2000-06-29 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds
SK16022001A3 (sk) * 1999-05-13 2002-09-10 American Cyanamid Company Adjuvantné kombinované prostriedky
WO2000071671A2 (en) * 1999-05-26 2000-11-30 New York University New mutant genes in familial british dementia and familial danish dementia
ES2337017T3 (es) * 1999-10-13 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Procedimiento para obtener respuestas inmunitarias celulares de proteinas.
US6605696B1 (en) * 1999-10-22 2003-08-12 Pfizer, Inc. Lawsonia intracellularis proteins, and related methods and materials
CA2410903A1 (en) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
EP1474447A2 (de) * 2002-02-08 2004-11-10 Immunovaccine Technologies Inc. Antigene zur immuno-schwangerschaftsverhütung
US7056515B2 (en) * 2002-02-08 2006-06-06 Immunovaccine Technologies Inc. Antigens for immunocontraception
US20040019339A1 (en) * 2002-07-26 2004-01-29 Sridhar Ranganathan Absorbent layer attachment
CA2521051C (en) * 2003-04-04 2012-03-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
RU2347586C2 (ru) * 2004-04-05 2009-02-27 Пфайзер Продактс Инк. Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CA2633772C (en) * 2005-12-22 2015-09-15 Ralph Leon Biemans Pneumococcal polysaccharide conjugate vaccine
CA2643322C (en) * 2006-02-24 2015-07-21 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
DK1989224T3 (da) * 2006-02-24 2011-02-14 Us Gov Health & Human Serv Immunogene peptider og anvendelsesmetoder
CA2649688A1 (en) * 2006-03-14 2007-09-20 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8608937B2 (en) * 2009-03-30 2013-12-17 Roche Diagnostics Operations, Inc. Biosensor with predetermined dose response curve and method of manufacturing

Also Published As

Publication number Publication date
DE60117164T2 (de) 2006-08-03
AU2002214861B2 (en) 2006-09-28
CA2428103A1 (en) 2002-05-16
US20140099358A1 (en) 2014-04-10
US20020110568A1 (en) 2002-08-15
US7824686B2 (en) 2010-11-02
US6793923B2 (en) 2004-09-21
ES2258108T3 (es) 2006-08-16
EP1333858B1 (de) 2006-02-08
US20090074853A1 (en) 2009-03-19
EP1333858B8 (de) 2006-06-14
AU1486102A (en) 2002-05-21
US8628937B2 (en) 2014-01-14
US20050019339A1 (en) 2005-01-27
CA2428103C (en) 2015-06-09
US20090092666A1 (en) 2009-04-09
WO2002038175A1 (en) 2002-05-16
JP2004512384A (ja) 2004-04-22
DE60117164D1 (de) 2006-04-20
EP1333858A1 (de) 2003-08-13
US9114174B2 (en) 2015-08-25
JP4164361B2 (ja) 2008-10-15

Similar Documents

Publication Publication Date Title
DE60117164D1 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
ATE386806T1 (de) Antigene polypeptide
DE60238471D1 (de) Proteosom-liposaccharid-vakzine-adjuvans
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
ATE70717T1 (de) Vermehrung der antigenimmunogenizitaet.
DK2181715T3 (da) Kunstige T-hjælpecelle-epitoper som immunstimulatorer for syntetiske peptidimmunogener
CA2297786A1 (en) New immunoprotective influenza antigen and its use in vaccination
DE69943359D1 (de) Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
MXPA01011660A (es) Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ATE542829T1 (de) Impfstoff
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
BR9506885A (pt) Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
BR9809656A (pt) Composição imunopotencializante
NZ206960A (en) Recombinant antigenic protein containing the amine acid sequence of an epitope of the circumsporozoite protein of a plasmodium species
MXPA03001235A (es) Purificacion de antigenos vhb para uso en vacunas.
ATE157537T1 (de) Liposomen, die versorgt werden mit t-helfer lympozyten zur unterstützung schwacher antigene als impfstoffe
WO1995026982A3 (en) Malaria peptides
WO2004078099A3 (en) Compositions and methods for the generation of protective immune response against malaria
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
WO2001085763A3 (en) Chimeric peptide immunogens their preparation and use
ATE258445T1 (de) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
DE60016806D1 (de) Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen
HK1048323A1 (en) Production of mammary secretion antibodies in farmanimals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties